Plain-English translation of NCT06532279 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called BMX-001, which is designed to protect healthy mouth tissue from damage caused by radiation therapy. You would receive either BMX-001 or a placebo (an inactive substance) along with your standard radiation and chemotherapy treatment for head and neck cancer. The study wants to see if this medication can reduce the severe mouth sores that commonly occur during this type of cancer treatment.
Radiation and chemotherapy for head and neck cancer often cause severe mouth sores, pain, and difficulty eating—side effects that significantly impact patients' quality of life during treatment. This medication is being tested to see if it can protect the mouth tissue and reduce these painful complications.
You likely qualify if…
You likely don't qualify if…
You would receive your standard radiation therapy (daily treatments, 5 days per week for 7 weeks) and chemotherapy as planned. In addition, you would receive injections of either BMX-001 or placebo—starting before your first radiation and chemotherapy doses, then twice weekly for 8 weeks. You would have imaging scans (CT or MRI) on study and may be asked to donate blood samples. The study will track your mouth sores, skin reactions, and other side effects through questionnaires and medical exams during and after your treatment.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States